0001140361-21-020643.txt : 20210611
0001140361-21-020643.hdr.sgml : 20210611
20210611161524
ACCESSION NUMBER: 0001140361-21-020643
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210610
FILED AS OF DATE: 20210611
DATE AS OF CHANGE: 20210611
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: EVNIN ANTHONY B
CENTRAL INDEX KEY: 0001239241
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-31141
FILM NUMBER: 211011451
MAIL ADDRESS:
STREET 1: C/O VENROCK ASSOCIATES
STREET 2: 7 BRYANT PARK, 23RD FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10018
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: INFINITY PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001113148
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 330655706
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1100 MASSACHUSETTS AVENUE
STREET 2: FLOOR 4
CITY: CAMBRIDGE
STATE: MA
ZIP: 02138
BUSINESS PHONE: 6174531000
MAIL ADDRESS:
STREET 1: 1100 MASSACHUSETTS AVENUE
STREET 2: FLOOR 4
CITY: CAMBRIDGE
STATE: MA
ZIP: 02138
FORMER COMPANY:
FORMER CONFORMED NAME: INFINITY PHARMACEUTICALS, INC./NEW/
DATE OF NAME CHANGE: 20060913
FORMER COMPANY:
FORMER CONFORMED NAME: DISCOVERY PARTNERS INTERNATIONAL INC
DATE OF NAME CHANGE: 20000428
4
1
form4.xml
FORM 4
X0306
4
2021-06-10
0001113148
INFINITY PHARMACEUTICALS, INC.
INFI
0001239241
EVNIN ANTHONY B
C/O INFINITY PHARMACEUTICALS, INC.
1100 MASSACHUSETTS AVENUE, FLOOR 4
CAMBRIDGE
MA
02138
true
Common Stock
2021-06-10
4
A
0
3061
3.43
A
169025
D
Stock Option (right to buy)
3.43
2021-06-10
4
A
0
30000
0
A
2031-06-09
Common Stock
30000
30000
D
Pursuant to the issuer's non-employee director compensation program, the reporting person has elected to receive this grant of shares in lieu of cash as payment of approximately 25% of such person's $42,000 annual retainer for service as a director.
The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as a director of the issuer.
/s/ Anthony B. Evnin
2021-06-11